155 related articles for article (PubMed ID: 11159981)
1. Inhibition of bacterial superantigens by peptides and antibodies.
Visvanathan K; Charles A; Bannan J; Pugach P; Kashfi K; Zabriskie JB
Infect Immun; 2001 Feb; 69(2):875-84. PubMed ID: 11159981
[TBL] [Abstract][Full Text] [Related]
2. Superantigen antagonist protects against lethal shock and defines a new domain for T-cell activation.
Arad G; Levy R; Hillman D; Kaempfer R
Nat Med; 2000 Apr; 6(4):414-21. PubMed ID: 10742148
[TBL] [Abstract][Full Text] [Related]
3. Defense against biologic warfare with superantigen toxins.
Kaempfer R; Arad G; Levy R; Hillman D
Isr Med Assoc J; 2002 Jul; 4(7):520-3. PubMed ID: 12120463
[TBL] [Abstract][Full Text] [Related]
4. Broad-spectrum immunity against superantigens is elicited in mice protected from lethal shock by a superantigen antagonist peptide.
Arad G; Hillman D; Levy R; Kaempfer R
Immunol Lett; 2004 Feb; 91(2-3):141-5. PubMed ID: 15019282
[TBL] [Abstract][Full Text] [Related]
5. Superantigen antagonist blocks Th1 cytokine gene induction and lethal shock.
Arad G; Hillman D; Levy R; Kaempfer R
J Leukoc Biol; 2001 Jun; 69(6):921-7. PubMed ID: 11404377
[TBL] [Abstract][Full Text] [Related]
6. A broad-spectrum inhibitory peptide against staphylococcal enterotoxin superantigen SEA, SEB and SEC.
Wang S; Li Y; Xiong H; Cao J
Immunol Lett; 2008 Dec; 121(2):167-72. PubMed ID: 19028523
[TBL] [Abstract][Full Text] [Related]
7. Peptide antagonists of superantigen toxins.
Kaempfer R
Mol Divers; 2004; 8(2):113-20. PubMed ID: 15209162
[TBL] [Abstract][Full Text] [Related]
8. Carboxy-terminal residues of major histocompatibility complex class II-associated peptides control the presentation of the bacterial superantigen toxic shock syndrome toxin-1 to T cells.
Wen R; Broussard DR; Surman S; Hogg TL; Blackman MA; Woodland DL
Eur J Immunol; 1997 Mar; 27(3):772-81. PubMed ID: 9079821
[TBL] [Abstract][Full Text] [Related]
9. Defining a novel domain of staphylococcal toxic shock syndrome toxin-1 critical for major histocompatibility complex class II binding, superantigenic activity, and lethality.
Kum WW; Laupland KB; Chow AW
Can J Microbiol; 2000 Feb; 46(2):171-9. PubMed ID: 10721486
[TBL] [Abstract][Full Text] [Related]
10. Molecular structure of staphylococcus and streptococcus superantigens.
Schlievert PM; Bohach GA; Ohlendorf DH; Stauffacher CV; Leung DY; Murray DL; Prasad GS; Earhart CA; Jablonski LM; Hoffmann ML; Chi YI
J Clin Immunol; 1995 Nov; 15(6 Suppl):4S-10S. PubMed ID: 8613491
[TBL] [Abstract][Full Text] [Related]
11. Antibodies to highly conserved peptide sequence of staphylococcal and streptococcal superantigens in Kawasaki disease.
Gupta-Malhotra M; Viteri-Jackson A; Thomas W; Zabriskie JB
Exp Mol Pathol; 2004 Apr; 76(2):117-21. PubMed ID: 15010289
[TBL] [Abstract][Full Text] [Related]
12. Identification from a phage display library of peptides that bind to toxic shock syndrome toxin-1 and that inhibit its binding to major histocompatibility complex (MHC) class II molecules.
Sato A; Ida N; Fukuyama M; Miwa K; Kazami J; Nakamura H
Biochemistry; 1996 Aug; 35(32):10441-7. PubMed ID: 8756700
[TBL] [Abstract][Full Text] [Related]
13. Identification of binding domains on the superantigen, toxic shock syndrome-1, for class II MHC molecules.
Soos JM; Russell JK; Jarpe MA; Pontzer CH; Johnson HM
Biochem Biophys Res Commun; 1993 Mar; 191(3):1211-7. PubMed ID: 8466498
[TBL] [Abstract][Full Text] [Related]
14. Cellular and molecular mechanisms of immune activation by microbial superantigens: studies using toxic shock syndrome toxin-1.
Chatila T; Scholl P; Ramesh N; Trede N; Fuleihan R; Morio T; Geha RS
Chem Immunol; 1992; 55():146-71. PubMed ID: 1418616
[No Abstract] [Full Text] [Related]
15. Staphylococcal and streptococcal pyrogenic toxins involved in toxic shock syndrome and related illnesses.
Bohach GA; Fast DJ; Nelson RD; Schlievert PM
Crit Rev Microbiol; 1990; 17(4):251-72. PubMed ID: 2206394
[TBL] [Abstract][Full Text] [Related]
16. Mapping of multiple binding domains of the superantigen staphylococcal enterotoxin A for HLA.
Griggs ND; Pontzer CH; Jarpe MA; Johnson HM
J Immunol; 1992 Apr; 148(8):2516-21. PubMed ID: 1560207
[TBL] [Abstract][Full Text] [Related]
17. Major histocompatibility complex class II-associated peptides determine the binding of the superantigen toxic shock syndrome toxin-1.
von Bonin A; Ehrlich S; Malcherek G; Fleischer B
Eur J Immunol; 1995 Oct; 25(10):2894-8. PubMed ID: 7589089
[TBL] [Abstract][Full Text] [Related]
18. Human CD4 and human major histocompatibility complex class II (DQ6) transgenic mice: supersensitivity to superantigen-induced septic shock.
Yeung RS; Penninger JM; Kündig T; Khoo W; Ohashi PS; Kroemer G; Mak TW
Eur J Immunol; 1996 May; 26(5):1074-82. PubMed ID: 8647170
[TBL] [Abstract][Full Text] [Related]
19. Conservation and variation in superantigen structure and activity highlighted by the three-dimensional structures of two new superantigens from Streptococcus pyogenes.
Arcus VL; Proft T; Sigrell JA; Baker HM; Fraser JD; Baker EN
J Mol Biol; 2000 May; 299(1):157-68. PubMed ID: 10860729
[TBL] [Abstract][Full Text] [Related]
20. Binding of superantigen toxins into the CD28 homodimer interface is essential for induction of cytokine genes that mediate lethal shock.
Arad G; Levy R; Nasie I; Hillman D; Rotfogel Z; Barash U; Supper E; Shpilka T; Minis A; Kaempfer R
PLoS Biol; 2011 Sep; 9(9):e1001149. PubMed ID: 21931534
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
